p53 and MicroRNA-34 Are Suppressors of Canonical Wnt Signaling

The tumor suppressor p53 activates miRNA-34 to inhibit Wnt signaling and colorectal cancer cell invasiveness. p53 Activates MicroRNA-34 to Inhibit Wnt Signaling The tumor suppressor p53 is missing or nonfunctional in many cancers, whereas the canonical Wnt signaling pathway is frequently activated. Here, Kim et al. show that p53 restrained Wnt signaling during Xenopus development, whereas loss of p53 function led to aberrant activation of the canonical Wnt signaling pathway, with microRNA-34 (miR-34) providing the connection between the two. They found that p53 stimulated production of miR-34, which, in turn, targeted key genes in the Wnt signaling pathway. Analyses of gene expression data sets indicated that loss of p53 or miR-34 function was associated with activation of Wnt signaling in human cancers; moreover, loss of p53 function increased Wnt signaling in colon cancer cells in vitro. In p53-mutant colon cancer cells, miR-34 attenuated Wnt signaling and decreased the invasiveness of these cells in vitro. Thus, the p53–miR-34–Wnt pathway appears to be crucial not only during development but also for p53’s tumor suppressor function. Although loss of p53 function and activation of canonical Wnt signaling cascades are frequently coupled in cancer, the links between these two pathways remain unclear. We report that p53 transactivated microRNA-34 (miR-34), which consequently suppressed the transcriptional activity of β-catenin–T cell factor and lymphoid enhancer factor (TCF/LEF) complexes by targeting the untranslated regions (UTRs) of a set of conserved targets in a network of genes encoding elements of the Wnt pathway. Loss of p53 function increased canonical Wnt signaling by alleviating miR-34–specific interactions with target UTRs, and miR-34 depletion relieved p53-mediated Wnt repression. Gene expression signatures reflecting the status of β-catenin–TCF/LEF transcriptional activity in breast cancer and pediatric neuroblastoma patients were correlated with p53 and miR-34 functional status. Loss of p53 or miR-34 contributed to neoplastic progression by triggering the Wnt-dependent, tissue-invasive activity of colorectal cancer cells. Further, during development, miR-34 interactions with the β-catenin UTR affected Xenopus body axis polarity and the expression of Wnt-dependent patterning genes. These data provide insight into the mechanisms by which a p53–miR-34 network restrains canonical Wnt signaling cascades in developing organisms and human cancer.

[1]  Christopher A. Maher,et al.  A p53/miRNA-34 axis regulates Snail1-dependent cancer cell epithelial–mesenchymal transition , 2011, The Journal of cell biology.

[2]  B. Williams,et al.  LRP6 Mediates cAMP Generation by G Protein–Coupled Receptors Through Regulating the Membrane Targeting of Gαs , 2011, Science Signaling.

[3]  M. Hung,et al.  p53 regulates epithelial-mesenchymal transition (EMT) and stem cell properties through modulating miRNAs , 2010, Nature Cell Biology.

[4]  H. Hamm,et al.  Gβγ Activates GSK3 to Promote LRP6-Mediated β-Catenin Transcriptional Activity , 2010, Science Signaling.

[5]  S. Weiss,et al.  Induction of a MT1-MMP and MT2-MMP-dependent basement membrane transmigration program in cancer cells by Snail1 , 2009, Proceedings of the National Academy of Sciences.

[6]  Peter W. Reddien,et al.  Wnt Signaling and the Polarity of the Primary Body Axis , 2009, Cell.

[7]  J. Mehrkens,et al.  Novel Molecular Stereotactic Biopsy Procedures Reveal Intratumoral Homogeneity of Loss of Heterozygosity of 1p/19q and TP53 Mutations in World Health Organization Grade II Gliomas , 2009, Journal of neuropathology and experimental neurology.

[8]  Lawrence A. Donehower,et al.  20 years studying p53 functions in genetically engineered mice , 2009, Nature Reviews Cancer.

[9]  Pier Paolo Di Fiore,et al.  The Tumor Suppressor p53 Regulates Polarity of Self-Renewing Divisions in Mammary Stem Cells , 2009, Cell.

[10]  Min Zhang,et al.  MicroRNA miR-34 Inhibits Human Pancreatic Cancer Tumor-Initiating Cells , 2009, PloS one.

[11]  R. Stephens,et al.  Downregulated MicroRNA-200a in Meningiomas Promotes Tumor Growth by Reducing E-Cadherin and Activating the Wnt/β-Catenin Signaling Pathway , 2009, Molecular and Cellular Biology.

[12]  C. Mayr,et al.  Widespread Shortening of 3′UTRs by Alternative Cleavage and Polyadenylation Activates Oncogenes in Cancer Cells , 2009, Cell.

[13]  C. Croce,et al.  MicroRNAs in Cancer. , 2009, Annual review of medicine.

[14]  Marc Ladanyi,et al.  WNT/TCF Signaling through LEF1 and HOXB9 Mediates Lung Adenocarcinoma Metastasis , 2009, Cell.

[15]  Jennifer A Fulcher,et al.  Phagocytes, Granulocytes, and Myelopoiesis , 2022 .

[16]  Brian D Athey,et al.  New class of microRNA targets containing simultaneous 5'-UTR and 3'-UTR interaction sites. , 2009, Genome research.

[17]  G. Pan,et al.  MicroRNA-145 Regulates OCT4, SOX2, and KLF4 and Represses Pluripotency in Human Embryonic Stem Cells , 2009, Cell.

[18]  J. G. Patton,et al.  Regulation of zebrafish fin regeneration by microRNAs , 2008, Proceedings of the National Academy of Sciences.

[19]  V. Rotter,et al.  p53 Plays a Role in Mesenchymal Differentiation Programs, in a Cell Fate Dependent Manner , 2008, PloS one.

[20]  I. Gérin,et al.  The microRNA miR-8 is a conserved negative regulator of Wnt signaling , 2008, Proceedings of the National Academy of Sciences.

[21]  M. Yamakuchi,et al.  miR-34a repression of SIRT1 regulates apoptosis , 2008, Proceedings of the National Academy of Sciences.

[22]  J Khan,et al.  The MYCN oncogene is a direct target of miR-34a , 2008, Oncogene.

[23]  Walter Birchmeier,et al.  Deciphering the function of canonical Wnt signals in development and disease: conditional loss- and gain-of-function mutations of beta-catenin in mice. , 2008, Genes & development.

[24]  Carola Berking,et al.  Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer , 2008, Cell cycle.

[25]  M. Toyota,et al.  Epigenetic silencing of microRNA-34b/c and B-cell translocation gene 4 is associated with CpG island methylation in colorectal cancer. , 2008, Cancer research.

[26]  T. Brabletz,et al.  A reciprocal repression between ZEB1 and members of the miR-200 family promotes EMT and invasion in cancer cells , 2008, EMBO reports.

[27]  G. Goodall,et al.  The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1 , 2008, Nature Cell Biology.

[28]  Eduardo Sontag,et al.  Transcriptional control of human p53-regulated genes , 2008, Nature Reviews Molecular Cell Biology.

[29]  Andrew G. Hall,et al.  Identification of candidate genes involved in neuroblastoma progression by combining genomic and expression microarrays with survival data , 2007, Oncogene.

[30]  Uyen Tran,et al.  MicroRNA control of Nodal signalling , 2007, Nature.

[31]  Ying Feng,et al.  Supplemental Data P53-mediated Activation of Mirna34 Candidate Tumor-suppressor Genes , 2022 .

[32]  R. Stallings,et al.  MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells , 2007, Oncogene.

[33]  L. Lim,et al.  A microRNA component of the p53 tumour suppressor network , 2007, Nature.

[34]  Michael A. Beer,et al.  Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. , 2007, Molecular cell.

[35]  T. Golub,et al.  Impaired microRNA processing enhances cellular transformation and tumorigenesis , 2007, Nature Genetics.

[36]  A. Børresen-Dale,et al.  TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes , 2007, Oncogene.

[37]  J. G. Patton,et al.  Zebrafish miR-214 modulates Hedgehog signaling to specify muscle cell fate , 2007, Nature Genetics.

[38]  S. Weiss,et al.  A Wnt–Axin2–GSK3β cascade regulates Snail1 activity in breast cancer cells , 2006, Nature Cell Biology.

[39]  H. Clevers,et al.  AU-rich elements and alternative splicing in the β-catenin 3′UTR can influence the human β-catenin mRNA stability , 2006 .

[40]  A. Levine,et al.  The P53 pathway: what questions remain to be explored? , 2006, Cell Death and Differentiation.

[41]  Z. Weng,et al.  A Global Map of p53 Transcription-Factor Binding Sites in the Human Genome , 2006, Cell.

[42]  H. Clevers,et al.  AU-rich elements and alternative splicing in the beta-catenin 3'UTR can influence the human beta-catenin mRNA stability. , 2006, Experimental cell research.

[43]  E. Connolly,et al.  Chromosome 1p and 11q Deletions and Outcome in Neuroblastoma. , 2006, Neurosurgery.

[44]  P. Hall,et al.  An expression signature for p53 status in human breast cancer predicts mutation status, transcriptional effects, and patient survival. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[45]  V. Kim MicroRNA biogenesis: coordinated cropping and dicing , 2005, Nature Reviews Molecular Cell Biology.

[46]  S. Weiss,et al.  Wnt-dependent Regulation of the E-cadherin Repressor Snail* , 2005, Journal of Biological Chemistry.

[47]  R. Nusse,et al.  The Wnt signaling pathway in development and disease. , 2004, Annual review of cell and developmental biology.

[48]  R. Nusse,et al.  Convergence of Wnt, ß-Catenin, and Cadherin Pathways , 2004, Science.

[49]  C. Croce,et al.  Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[50]  D. Bartel MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[51]  R. Eeles,et al.  Li-Fraumeni and related syndromes: correlation between tumor type, family structure, and TP53 genotype. , 2003, Cancer research.

[52]  Robert D Cardiff,et al.  Impact of p53 loss on reversal and recurrence of conditional Wnt-induced tumorigenesis. , 2003, Genes & development.

[53]  R. Bernards,et al.  A System for Stable Expression of Short Interfering RNAs in Mammalian Cells , 2002, Science.

[54]  Mitsutoshi Nakamura,et al.  Phenotype versus genotype correlation in oligodendrogliomas and low-grade diffuse astrocytomas , 2002, Acta Neuropathologica.

[55]  Hans Clevers,et al.  The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells. , 2002, Cell.

[56]  A. Sparks,et al.  Identification of c-MYC as a target of the APC pathway. , 1998, Science.

[57]  T. Soussi,et al.  Regulation of the specific DNA binding activity of Xenopus laevis p53: evidence for conserved regulation through the carboxy-terminus of the protein , 1998, Oncogene.

[58]  H. Varmus,et al.  Absence of p53 in a mouse mammary tumor model promotes tumor cell proliferation without affecting apoptosis. , 1997, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[59]  M. Schwab,et al.  Genomic instability in Ip and human malignancies , 1996, Genes, chromosomes & cancer.

[60]  Y. S. Kim,et al.  The effects of wild type p53 tumor suppressor gene expression on the normal human cervical epithelial cells or human epidermal keratinocytes transformed with human papillomavirus type 16 DNA. , 1995, Yonsei medical journal.

[61]  D. Pinkel,et al.  Deficiency of p53 accelerates mammary tumorigenesis in Wnt-1 transgenic mice and promotes chromosomal instability. , 1995, Genes & development.

[62]  P. McCrea,et al.  Embryonic axis induction by the armadillo repeat domain of beta- catenin: evidence for intracellular signaling , 1995, The Journal of cell biology.

[63]  M. Oshimura,et al.  Suppression of tumourigenicity in human colon carcinoma cells by introduction of normal chromosome 1p36 region. , 1993, Oncogene.

[64]  L. Donehower,et al.  Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours , 1992, Nature.

[65]  B. Vogelstein,et al.  A genetic model for colorectal tumorigenesis , 1990, Cell.

[66]  M. Oren,et al.  Wild-type p53 can inhibit oncogene-mediated focus formation. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[67]  A. Levine,et al.  The p53 proto-oncogene can act as a suppressor of transformation , 1989, Cell.

[68]  P. Green,et al.  Mapping the gene for hereditary cutaneous malignant melanoma-dysplastic nevus to chromosome 1p. , 1989, The New England journal of medicine.

[69]  A. Knudson Mutation and cancer: statistical study of retinoblastoma. , 1971, Proceedings of the National Academy of Sciences of the United States of America.